Elisabeth Hofmeister, M.Sc.
Doktorandin und wissenschaftliche Mitarbeiterin
Innovation and Entrepreneurship Research
+49 89 24246-579
elisabeth.hofmeister(at)ip.mpg.de
Arbeitsbereiche:
Innovationsökonomik, Gesundheitsökonomik, Industrieökonomik, Wettbewerbsökonomik
Wissenschaftlicher Werdegang
Seit 04/2022
Postgraduales Studium Betriebswirtschaftliche Forschung (MBR), Ludwig-Maximilians-Universität (LMU) München
Seit 10/2021
Wissenschaftliche Mitarbeiterin und Doktorandin am Max-Planck-Institut für Innovation und Wettbewerb (Innovation and Entrepreneurship Research)
09/2018 – 09/2021
Master of Science (M.Sc.) in Management & Technology mit Major in Chemie, Technische Universität München (TUM)
08/2016 – 12/2016
Auslandssemester an der University of Hong Kong
09/2014 – 09/2018
Bachelor of Science (B.Sc.) in Management & Technology mit Minor in Chemie, Technische Universität München (TUM)
Beruflicher Werdegang
06/2020 – 09/2021
Werkstudentin Consulting Services, IQVIA Commercial GmbH & Co. OHG, München
09/2019 – 12/2019
Praktikum Business Development, Fresenius Kabi Asia Pacific Ltd., Hong Kong
04/2019 – 09/2019
Projektstudium „Forum der Zukunft”, Deutsches Museum, München
09/2018 – 07/2019
Werkstudentin Business Development, InGeneron GmbH, München
04/2018 – 07/2018
Praktikum CFO Office / Global Business Services, Fresenius Kabi Deutschland GmbH, Bad Homburg
10/2017 – 03/2018
Praktikum Audit Corporate, KPMG AG Wirtschaftsprüfungsgesellschaft, München
03/2017 – 05/2017
Projektstudium „Internationalität in Human Resources“, MAN Truck & Bus AG, München
08/2015 – 06/2016
Werkstudentin Consulting, ROI Management Consulting AG, München
Stipendien
11/2025
Add-on Fellowship for Interdisciplinary Science and Transfer, Joachim Herz Stiftung
Seit 10/2018
TUM Finance and Accounting Selected Talents (TUMfast)
Publikationen
Diskussionspapiere
(2024). Regulating Genome-Edited Products – an International Trade Law Perspective, Max Planck Institute for Innovation & Competition Research Paper, No. 24-13.
- This paper provides a preliminary assessment of the compliance of national marketing regulation concerning genome-edited food products with international trade law. It presents an overview of global regulatory trends in this area and focuses on the compatibility of the diverging regulatory approaches with World Trade Organization (WTO) law, particularly the Agreement on Sanitary and Phytosanitary Measures (SPS) and the Agreement on Technical Barriers to Trade (TBT). Overall, the analysis finds significant potential for trade concerns under WTO law. As consumer choice is becoming the primary justification for labelling requirements, the focus of the assessment of NGT related measures will likely shift towards the TBT Agreement.
- Available at SSRN
(2022). CRISPR/Cas Technology and Innovation: Mapping Patent Law Issues, Max Planck Institute for Innovation & Competition Research Paper, No. 22-06.
- The paper provides a systematic overview of issues arising at the interface between CRISPR/Cas technology and patent law. In particular, it examines aspects related to the patentability of CRISPR/Cas-based methods of genome editing, on the one hand, and access to patented technologies, in view of the expanding CRISPR patent landscape, on the other hand. On the whole, our findings show that the case of CRISPR/Cas technology is prototypical of the policy dilemma in patent law as to how to balance economic incentives of multiple innovators in a cumulative innovation setting. The reviewed technical, legal and economic factors suggest the preconditions for technology underutilisation. While this paper presents the results of the exploratory phase of research, it sets a framework for the further, more targeted interdisciplinary examination of the identified issues.
- Available at SSRN
Vorträge
15.10.2025
Commercial Regulation and the Production of Science: Evidence from Agricultural Biotechnology
Forschungsseminar, Max-Planck-Institut für Innovation und Wettbewerb
Tutzing
16.09.2025
Strategic Reserves – Shelved Innovation as a Real Option
Workshop on Intellectual Property Rights, Science and Innovation: Implications for Drug Discovery and the Health Sector, Università Cattolica del Sacro Cuore
Mailand, Italien
27.08.2025
Strategic Reserves – Shelved Innovation as a Real Option
8th Lindau Nobel Meeting in Economic Sciences, Foundation Lindau Nobel Laureate Meetings
Lindau
27.07.2025
Strategic Reserves – Shelved Innovation as a Real Option
85th Annual Meeting of the Academy of Management (AoM)
Kopenhagen, Dänemark
06.06.2025
Strategic Reserves – Shelved Innovation as a Real Option
HPI-ZEW-DIW Workshop on Applied Economics in Digital Health, ZEW
Mannheim
27.03.2025
Strategic Reserves – Shelved Innovation as a Real Option
Forschungsseminar, Max-Planck-Institut für Innovation und Wettbewerb
Zugspitze
25.09.2024
Shelved Innovation – Evidence from the Pharmaceutical Industry
Forschungsseminar, Max-Planck-Institut für Innovation und Wettbewerb
Martinsried/Planegg
13.08.2024
Shelved Innovation – Evidence from the Pharmaceutical Industry
84th Annual Meeting of the Academy of Management (AoM)
Chicago, USA
07.05.2024
Shelved Innovation – Evidence from the Pharmaceutical Industry
MAXSI - Max Planck-Kopenhagen Strategy & Innovation Workshop, Copenhagen Business School
Kopenhagen, Dänemark
28.03.2024
Shelved Innovation – Evidence from the Pharmaceutical Industry
Forschungsseminar, Max-Planck-Institut für Innovation und Wettbewerb
Tutzing
30.11.2023
Shelved Innovation – Evidence from the Pharmaceutical Industry
Strategy & Innovation Brown Bag, Boston University
Boston, USA
27.02.2023
Quantification of Shelved Pharma Projects
Forschungsseminar, Max-Planck-Institut für Innovation und Wettbewerb
Frauenchiemsee
05.09.2022
More Progress on Shelving in Pharma – Updates on Text Analysis and Plan for Further Insights
Forschungsseminar, Max-Planck-Institut für Innovation und Wettbewerb
Bernried
06.07.2022
Einblicke in forschende Unternehmen durch die Betrachtung von Schubladen-Projekten
Symposium „Wissenschaftsforschung im Fokus – Potentiale und neue Perspektiven“, VolkswagenStiftung
Hannover
11.04.2022
Creating a Pool of Shelved Pharmaceutical Projects and Related Questions
Forschungsseminar, Max-Planck-Institut für Innovation und Wettbewerb
Ohlstadt